1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Biocon Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
- MORE
The strong prevalence of oncology indications is one of the key factors expected to trigger market growth during the forecast period. Vendors are conducting studies on target specific drugs to meet the gap between the demand and supply of these therapies. Factors including the increasing geriatric population and changes in lifestyle have also contributed to the oncology indications, in turn, contributing to the mTOR Inhibitors market growth during the forecast period. Analysts have predicted that the mTOR inhibitors market will register a CAGR of over 3% by 2023.
Market Overview
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Market Overview
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Biocon Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: RoA - Market share 2018-2023 (%)
Exhibit 18: Comparison by RoA
Exhibit 19: Oral therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Oral therapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Pipeline molecules with oral RoA
Exhibit 22: Intravenous therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Intravenous therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by RoA
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: New cases of cancer in US: 2015
Exhibit 43: Alternative therapies for oncology indications for which mTOR inhibitors are used
Exhibit 44: Side effects of mTOR inhibitors
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Approved drugs with respect to their cancer indications
Exhibit 47: Expansion of research areas of mTOR inhibitors
Exhibit 48: Patient assistance programs
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Biocon Ltd. - Vendor overview
Exhibit 55: Biocon Ltd. - Business segments
Exhibit 56: Biocon Ltd. - Organizational developments
Exhibit 57: Biocon Ltd. - Geographic focus
Exhibit 58: Biocon Ltd. - Segment focus
Exhibit 59: Biocon Ltd. - Key offerings
Exhibit 60: Biocon Ltd. - Key customers
Exhibit 61: Intas Pharmaceuticals Ltd. - Vendor overview
Exhibit 62: Intas Pharmaceuticals Ltd. - Business segments
Exhibit 63: Intas Pharmaceuticals Ltd. - Organizational developments
Exhibit 64: Intas Pharmaceuticals Ltd. - Key offerings
Exhibit 65: Intas Pharmaceuticals Ltd. - Key customers
Exhibit 66: Novartis AG - Vendor overview
Exhibit 67: Novartis AG - Business segments
Exhibit 68: Novartis AG - Organizational developments
Exhibit 69: Novartis AG - Geographic focus
Exhibit 70: Novartis AG - Segment focus
Exhibit 71: Novartis AG - Key offerings
Exhibit 72: Novartis AG - Key customers
Exhibit 73: Pfizer Inc. - Vendor overview
Exhibit 74: Pfizer Inc. - Business segments
Exhibit 75: Pfizer Inc. - Organizational developments
Exhibit 76: Pfizer Inc. - Geographic focus
Exhibit 77: Pfizer Inc. - Segment focus
Exhibit 78: Pfizer Inc. - Key offerings
Exhibit 79: Pfizer Inc. - Key customers
Exhibit 80: Zydus Cadila - Vendor overview
Exhibit 81: Zydus Cadila - Business segments
Exhibit 82: Zydus Cadila - Organizational developments
Exhibit 83: Zydus Cadila - Geographic focus
Exhibit 84: Zydus Cadila - Key offerings
Exhibit 85: Zydus Cadila - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by RoA
- Comparison by RoA
- Oral therapy - Market size and forecast 2018-2023
- Intravenous therapy - Market size and forecast 2018-2023
- Market opportunity by RoA
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Biocon Ltd.
- Intas Pharmaceuticals Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: RoA - Market share 2018-2023 (%)
Exhibit 18: Comparison by RoA
Exhibit 19: Oral therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Oral therapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Pipeline molecules with oral RoA
Exhibit 22: Intravenous therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Intravenous therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by RoA
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: New cases of cancer in US: 2015
Exhibit 43: Alternative therapies for oncology indications for which mTOR inhibitors are used
Exhibit 44: Side effects of mTOR inhibitors
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Approved drugs with respect to their cancer indications
Exhibit 47: Expansion of research areas of mTOR inhibitors
Exhibit 48: Patient assistance programs
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: Biocon Ltd. - Vendor overview
Exhibit 55: Biocon Ltd. - Business segments
Exhibit 56: Biocon Ltd. - Organizational developments
Exhibit 57: Biocon Ltd. - Geographic focus
Exhibit 58: Biocon Ltd. - Segment focus
Exhibit 59: Biocon Ltd. - Key offerings
Exhibit 60: Biocon Ltd. - Key customers
Exhibit 61: Intas Pharmaceuticals Ltd. - Vendor overview
Exhibit 62: Intas Pharmaceuticals Ltd. - Business segments
Exhibit 63: Intas Pharmaceuticals Ltd. - Organizational developments
Exhibit 64: Intas Pharmaceuticals Ltd. - Key offerings
Exhibit 65: Intas Pharmaceuticals Ltd. - Key customers
Exhibit 66: Novartis AG - Vendor overview
Exhibit 67: Novartis AG - Business segments
Exhibit 68: Novartis AG - Organizational developments
Exhibit 69: Novartis AG - Geographic focus
Exhibit 70: Novartis AG - Segment focus
Exhibit 71: Novartis AG - Key offerings
Exhibit 72: Novartis AG - Key customers
Exhibit 73: Pfizer Inc. - Vendor overview
Exhibit 74: Pfizer Inc. - Business segments
Exhibit 75: Pfizer Inc. - Organizational developments
Exhibit 76: Pfizer Inc. - Geographic focus
Exhibit 77: Pfizer Inc. - Segment focus
Exhibit 78: Pfizer Inc. - Key offerings
Exhibit 79: Pfizer Inc. - Key customers
Exhibit 80: Zydus Cadila - Vendor overview
Exhibit 81: Zydus Cadila - Business segments
Exhibit 82: Zydus Cadila - Organizational developments
Exhibit 83: Zydus Cadila - Geographic focus
Exhibit 84: Zydus Cadila - Key offerings
Exhibit 85: Zydus Cadila - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Biocon Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
- MORE
The analyst recognizes the following companies as the key players in the global mTOR inhibitors market: Biocon Ltd., Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., and Zydus Cadila.
Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the presence of patient assistance programs.”
According to the report, one of the major drivers for this market is the high target affinity and specificity of mTOR inhibitors.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of available therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the presence of patient assistance programs.”
According to the report, one of the major drivers for this market is the high target affinity and specificity of mTOR inhibitors.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of available therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Biocon Ltd.
- Intas Pharmaceuticals Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
Note: Product cover images may vary from those shown
